Should alpha interferon be used as primary treatment for hairy cell leukemia?
Giovanni Capnist(Ospedale San Bortolo), E Damasio(Istituto di Ematologia di Bologna), Teresa Lamparelli(Ospedale Policlinico San Martino), Carlo Bernasconi(University Hospital Foundation), G. Pagnucco, L Resegotti, Teodoro Chisesi(Ospedale Civile di Venezia), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Rosangela Invernizzi(University of Pavia), C. Guarnaccia(Ospedale Vincenzo Cervello), Giuseppe Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Achille Ambrosetti(International Extranodal Lymphoma Study Group), Gian Luigi Castoldi(University of Ferrara), Pietro Leoni(Marche Polytechnic University), Pietro Fabris(Azienda Sanitaria di Firenze), Massimo Federico(University of Modena and Reggio Emilia)
Cited by 9
Related Papers
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|PubMed|2006|909
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733